| Abstract text: |
In the cancer chemotherapy, the use of cytostatics induces most of the times unwanted side effects, altering the metabolic functionality of some healthy tissues and organs: lymph toxicity, neurotoxicity, profound immune suppression and hepatotoxicity. Cyclophosphamide is a frequently used drug in anticancer chemotherapy. This presents a form of inactive transport, it’s metabolism and activation being located at the liver level under the action of mirosomal enzymes releasing chemical and biological active compounds. Thus, the effect of this cytostatic is strictly dependent on liver’s functional status, it’s modification contributing significantly to diminish antitumoral action of cyclophosphamide. These aspects justify our studies that were focused on identifying hepatic structural modifications showed in conditions of cyclophosphamide administration to Wistar rats for 3 days consecutive. We have collected samples of hepatic tissue at 24 h, respectively at 10 days after the last administration. Overall analysis of hepatocytes show us the fact that there has been, mainly, an alteration of lipid metabolism, manifested by blocking and depositing lipidic drops in hepatocytes especially in perilobular hepatocytes. Also, the quantity of the vesicles pertaining to smooth endoplasmic reticulum is very increased, indicating an intensification of detoxifying processes due to drug intervention. There can be noticed areas of hemorrhagic focals, fact proving that CFA acts brutally on small blood vessels drastically modifying their permeability, this having an extravasation effect of some large fluid quantities forming edemas. At 10 days from the administration of the last dose of cyclophosphamide, the hepatocytes tend to normalize their structure, but mentioned morphologic aspects don’t reach the control group. Concluding, mentioned alterations at hepatic level by the cyclophosphamide administration proves the necessity to respect the period of morpho-functional reconstruction of the respective organ before initiating a new chemotherapy. |
